Intravenous Bisphosphonate Therapy in the Adult Patient with Osteogenesis Imperfecta: A Literature Review and Case Report

Osteogenesis Imperfecta (OI) defines a group of genetically varied connective tissue disorders where intravenous bisphosphonate (BP) therapy is common to manage the associated bone fragility. Due to this bone fragility, there is potential for these patients to be regarded as a high-risk group for BP-related osteonecrosis of the jaw (BRONJ). First documentation of BRONJ was in 2003; however few reports discuss the risk of BRONJ relative to BP therapy in patients with OI. Of these reported cases of BRONJ, all have been recorded in patients sixty years and over. As yet, no literature is available to show if OI in adults increases the risk of BRONJ. In this case, a 59-year-old male, receiving intravenous BP therapy for OI, underwent multiple dental extractions under local anesthesia. At subsequent review appointments, no clinical signs of BRONJ were detected.